GuoLine Advisory Pte Ltd Raises Holdings in Novo Nordisk A/S (NYSE:NVO)

GuoLine Advisory Pte Ltd increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 23.1% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 426,700 shares of the company's stock after purchasing an additional 80,200 shares during the quarter. Novo Nordisk A/S makes up approximately 3.1% of GuoLine Advisory Pte Ltd's investment portfolio, making the stock its 16th largest position. GuoLine Advisory Pte Ltd's holdings in Novo Nordisk A/S were worth $29,630,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the company. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL boosted its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $29,000. Transce3nd LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Novo Nordisk A/S during the fourth quarter worth $39,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 2.8%

NVO traded up $1.94 during mid-day trading on Friday, hitting $71.40. 11,185,051 shares of the stock were exchanged, compared to its average volume of 6,787,414. The firm's fifty day moving average is $65.58 and its two-hundred day moving average is $81.77. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market cap of $320.41 billion, a PE ratio of 21.70, a PEG ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion for the quarter. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on NVO. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.